Twist Bioscience (TWST, Financial) announced its second-quarter revenue of $92.79 million, surpassing the analysts' expectations of $92.04 million. The company is entering a new phase with the introduction of Atlas Data Storage, a strategic move aimed at advancing DNA data storage technology. This initiative is expected to help Twist accelerate its progress towards profitability. According to CEO Emily Leproust, the launch allows the company to operate as two distinct entities, each dedicated to the development and commercialization of innovative products and services while enhancing customer engagement.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 11 analysts, the average target price for Twist Bioscience Corp (TWST, Financial) is $53.74 with a high estimate of $65.00 and a low estimate of $45.00. The average target implies an upside of 36.96% from the current price of $39.24. More detailed estimate data can be found on the Twist Bioscience Corp (TWST) Forecast page.
Based on the consensus recommendation from 13 brokerage firms, Twist Bioscience Corp's (TWST, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Twist Bioscience Corp (TWST, Financial) in one year is $59.61, suggesting a upside of 51.91% from the current price of $39.24. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Twist Bioscience Corp (TWST) Summary page.
